Jun 18, 2020
Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China
Jun 13, 2020
Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections
May 08, 2020
Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes
Jan 16, 2020
FDA approves Ozempic® for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease, updates Rybelsus® label
Jun 17, 2019
FDA approves Victoza® for the treatment of type 2 diabetes in children and adolescents aged 10-17 years
Jun 11, 2019
Oral Semaglutide Reduces Occurrence of Major Cardiac Events in People with Type 2 Diabetes With High Cardiovascular Risk
Jun 08, 2019
Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79 Scientific Sessions®
May 22, 2019
Novo Nordisk to present data on oral semaglutide at the 79th Annual American Diabetes Association Scientific Sessions
Mar 21, 2019
North America Glucagon like Peptide - 1 Agonists Market 2019-2024 by Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide) & Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
Dec 05, 2018
Visiongain Report Looks at Opportunities Within the $6.3bn Anti-Obesity Drugs Market
Nov 13, 2018
Mordor Intelligence, LLP. Contributes to the Diabetes Awareness Month by Granting Free Access to Their Real-Time Exhaustive Research on Diabetes Care Drugs
Oct 17, 2018
Global DPP-IV Inhibitors Markets 2016-2024 by Drugs (Sitagliptin, Vildagliptin, Saxagliptin & Others) & Segments (Sitagliptin, Saxagliptin, Linagliptin & Alogliptin)
Sep 27, 2018
Mordor Intelligence, LLP. Launches its Intelligence Center to Help Enterprises Involved in the Business of Diabetes Care Drugs, Make Smarter Decisions, Real Time
Jun 23, 2018
Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial
Mar 19, 2018
Semaglutide injection phase 2 data presented at ENDO demonstrated significant weight loss in adults with obesity
Nov 21, 2017
Health Canada approves Victoza® as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.